Icahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA.
Curr Diab Rep. 2021 Nov 4;21(11):44. doi: 10.1007/s11892-021-01415-2.
Diabetes during pregnancy increases the risk of maternal and fetal complications. This article reviews the types of CGM currently available, the glucose metrics which correlate with pregnancy outcomes, endocrine organization recommendations, clinical considerations for CGM implementation, and anticipated directions for future research.
CGM use during pregnancy is increasing, and recommendations for use have been incorporated into many organizations' consensus guidelines. Increased time spent within a target range of 63-140 mg/dL and lower mean glucose are associated with lower risk of neonatal complications including large for gestational age infants. Use of CGM during pregnancy can detect postprandial and nocturnal hyperglycemia missed by self-monitoring of blood glucose (SMBG) which can be used for prognosis and to guide pharmacologic interventions. The use of continuous glucose monitoring (CGM) during pregnancies complicated by type 1, type 2, and gestational diabetes has been shown to improve outcomes.
妊娠期间的糖尿病会增加母婴并发症的风险。本文综述了目前可用的连续血糖监测（CGM）类型、与妊娠结局相关的血糖指标、内分泌学会的推荐意见、CGM 实施的临床注意事项，以及对未来研究的预期方向。
妊娠期间 CGM 的使用正在增加，许多组织的共识指南中也纳入了 CGM 使用的推荐意见。在 63-140mg/dL 的目标范围内的时间增加和平均血糖降低与新生儿并发症（包括巨大儿）的风险降低相关。CGM 在妊娠期间的使用可以检测到通过自我监测血糖（SMBG）遗漏的餐后和夜间高血糖，这可用于预测和指导药物干预。在 1 型、2 型和妊娠糖尿病合并妊娠期间使用 CGM 已被证明可以改善结局。
